NEW YORK (GenomeWeb) – Editas Medicine has signed a deal potentially worth more than $90 million, giving Allergan the exclusive rights to license certain of its CRISPR genome editing-based treatments for eye diseases.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.
In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.
This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.